AUREOMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AUREOMYCIN (AUREOMYCIN).
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug) |
| Half-life | Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria) |
| Protein binding | 55–65% bound primarily to albumin |
| Volume of Distribution | 1.3–1.6 L/kg (exceeds total body water, indicating extensive tissue penetration) |
| Bioavailability | Oral: 30–40% (approximately); Topical: minimal systemic absorption (<5% through intact skin) |
| Onset of Action | Oral: 1–2 hours; Intravenous: 5–10 minutes after bolus; Topical: 24–48 hours for clinical improvement |
| Duration of Action | Oral: 6–8 hours; Intravenous: 12 hours (beyond MIC for sensitive organisms); Topical: sustained local effect for 12–24 hours |
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
| Dosage form | OINTMENT |
| Renal impairment | CrCl 10-50 mL/min: dose every 12-18 hours; CrCl <10 mL/min: dose every 24 hours |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use |
| Pediatric use | 8-12 years: 25-50 mg/kg/day orally divided every 6 hours; intravenous: 10-20 mg/kg/day divided every 12 hours; maximum 500 mg/day |
| Geriatric use | Reduce dose by 25-50% due to age-related renal decline; monitor renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AUREOMYCIN (AUREOMYCIN).
| Breastfeeding | Chlortetracycline is excreted in human milk. The milk-to-plasma ratio is unknown but tetracyclines are generally present in low concentrations. Potential risks to the breastfed infant include teeth discoloration and bone growth suppression, especially with prolonged exposure. Theoretical risk of photosensitivity. The American Academy of Pediatrics considers tetracyclines to be usually compatible with breastfeeding, but caution is advised for long-term use. Alternative agents are preferred. |
| Teratogenic Risk | Aureomycin (chlortetracycline) is a tetracycline antibiotic. Tetracyclines cross the placenta and may cause fetal harm. First trimester: limited data, but risk of teratogenic effects (neural tube defects, cardiovascular malformations) cannot be excluded; animal studies show embryotoxicity. Second and third trimesters: exposure may cause permanent discoloration of deciduous teeth (yellow-gray-brown) if administered after the 4th month of gestation due to deposition in developing teeth and bones. Risk of skeletal growth retardation. Avoid use during pregnancy unless no alternative. |
■ FDA Black Box Warning
Use during tooth development (last half of pregnancy, infancy, childhood to 8 years) may cause permanent tooth discoloration or enamel hypoplasia.
| Serious Effects |
Hypersensitivity to tetracyclines, pregnancy (especially second half), lactation, and children under 8 years.
| Precautions | May cause photosensitivity, renal toxicity (especially in patients with impaired renal function), and superinfection with prolonged use. Avoid use in children <8 years due to tooth discoloration. |
| Food/Dietary | Avoid dairy products (milk, yogurt, cheese) within 2 hours of dosing. Do not take with calcium-fortified foods or beverages. Separate from iron-rich foods or supplements by at least 2 hours. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal and hepatic function. In pregnancy, avoid use; if unavoidable, monitor fetal growth and development via ultrasound. Assess for signs of maternal hepatotoxicity, which is rare but serious. Monitor for neonatal jaundice and dental staining postpartum. |
| Fertility Effects | No specific data on chlortetracycline effects on human fertility. In animal studies, tetracyclines have been associated with impaired fertility at high doses. Effects on spermatogenesis and ovulation are not well-documented in humans. Use during pregnancy may affect fetal gonadal development theoretically, but no clinical evidence supports significant fertility impairment. |
| Clinical Pearls | Aureomycin (chlortetracycline) is a first-generation tetracycline antibiotic. It is photosensitizing; advise patients to avoid prolonged sun exposure. It chelates with divalent and trivalent cations (e.g., calcium, iron, magnesium, aluminum), reducing oral absorption. Administer on an empty stomach, at least 1 hour before or 2 hours after meals or dairy products. Monitor for suprainfections, particularly Clostridioides difficile-associated diarrhea and vaginal candidiasis. Avoid in children under 8 years of age and in pregnancy due to risk of permanent tooth discoloration and bone growth impairment. |
| Patient Advice | Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals. · Avoid taking with dairy products, antacids, iron supplements, or multivitamins as they reduce absorption. · Use sunscreen and protective clothing when outdoors to prevent severe sunburn. · Complete the full course of therapy even if you feel better. · Report persistent diarrhea, vaginal itching, or skin rash to your healthcare provider. |